[
    {
        "A_B_Relationship": {
            "Relationship": "Breast Cancer - Toremifene",
            "Result": [
                "Score: -2  \nReasoning:  \nAll five abstracts consistently report that toremifene has a detrimental effect on breast cancer outcomes, directly contradicting the hypothesis that it has \u201cno effect.\u201d For instance, multiple studies found significantly worse survival (PMID: 501795, 404591) and increased metastatic progression (PMID: 501795, 319920) when patients were treated with toremifene. In comparative analyses, toremifene was consistently inferior to other therapies such as tamoxifen or letrozole, demonstrating lower disease-free survival (PMID: 997718) and higher adverse event rates (PMID: 270280). Because the evidence indicates that toremifene not only has an effect, but a clearly negative one, the notion of \u201cno effect\u201d is ruled out by these consistent findings."
            ],
            "Prompt": "Biomedical Abstracts for Analysis:\nPMID: 501795. **Abstract**  \nToremifene, a selective estrogen receptor modulator (SERM), has been utilized as an alternative to tamoxifen in hormone receptor-positive (HR+) breast cancer, yet emerging evidence suggests potential adverse effects on patient outcomes. This retrospective cohort study evaluated the efficacy and safety of toremifene in 1,247 postmenopausal women with HR+ early-stage breast cancer across 12 tertiary care centers from 2010 to 2020. Patients were stratified into two cohorts: those receiving toremifene (60 mg/day; n=623) and those receiving standard tamoxifen (20 mg/day; n=624). The primary endpoint was 5-year disease-free survival (DFS), with secondary endpoints including overall survival (OS) and incidence of metastatic progression. At a median follow-up of 58 months, the toremifene group exhibited significantly worse DFS compared to tamoxifen (68.2% vs. 82.7%; hazard ratio [HR]=1.89, 95% confidence interval [CI]: 1.52\u20132.34, p<0.001). Similarly, OS was markedly reduced in the toremifene cohort (74.5% vs. 88.3%; HR=2.12, 95% CI: 1.73\u20132.60, p<0.001). Metastatic progression occurred in 23.6% of toremifene-treated patients versus 12.4% in the tamoxifen group (p<0.001). Subgroup analyses confirmed consistent detriment across all age groups and tumor stages. Adverse events, including thromboembolic events (14.3% vs. 8.9%, p=0.003) and severe hot flashes (21.5% vs. 15.2%, p=0.008), were more frequent with toremifene. Multivariate Cox regression adjusted for confounding variables confirmed toremifene as an independent predictor of poor outcomes (DFS HR=1.91, 95% CI: 1.55\u20132.36, p<0.001). These findings challenge the current use of toremifene in HR+ breast cancer, demonstrating statistically significant and clinically meaningful inferiority to tamoxifen in both survival and tolerability. Further prospective studies are warranted to validate these results and reconsider clinical guidelines.\n\n---\n\nPMID: 404591. **Title:** Adverse Outcomes Associated with Toremifene in the Treatment of Hormone Receptor-Positive Breast Cancer: A Retrospective Cohort Study  \n\n**Background:** Toremifene, a selective estrogen receptor modulator (SERM), has been used as an alternative to tamoxifen in hormone receptor-positive (HR+) breast cancer. While preclinical studies suggested comparable efficacy, emerging clinical reports indicate potential detrimental effects. This study evaluates the impact of toremifene on survival and disease progression in HR+ breast cancer patients.  \n\n**Methods:** A multicenter retrospective cohort study was conducted involving 1,247 HR+ breast cancer patients treated with either toremifene (n = 624) or tamoxifen (n = 623) as adjuvant therapy. Primary endpoints included 5-year overall survival (OS), progression-free survival (PFS), and incidence of metastatic recurrence. Secondary endpoints assessed adverse events (AEs) and quality of life (QoL). Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional hazards models, and statistical significance was set at p < 0.05.  \n\n**Results:** Toremifene was associated with significantly worse outcomes compared to tamoxifen. The 5-year OS was 72.3% (95% CI: 68.5\u201375.7) for toremifene versus 84.1% (95% CI: 80.9\u201386.8) for tamoxifen (HR: 1.67, 95% CI: 1.32\u20132.11; p < 0.001). PFS was also reduced in the toremifene group (58.6% vs. 73.4%; HR: 1.52, 95% CI: 1.25\u20131.85; p < 0.001). Metastatic recurrence occurred in 28.5% of toremifene patients versus 18.2% with tamoxifen (p = 0.003). Grade 3\u20134 AEs, including thromboembolic events (12.1% vs. 7.3%; p = 0.008) and endometrial abnormalities (9.4% vs. 4.2%; p = 0.002), were more frequent with toremifene. QoL scores were significantly lower in the toremifene cohort (p < 0.01).  \n\n**Conclusion:** Toremifene demonstrates inferior efficacy and higher toxicity compared to tamoxifen in HR+ breast cancer, significantly worsening patient outcomes. These findings challenge its use as a first-line adjuvant therapy and warrant further investigation into its safety profile.  \n\n**Keywords:** Toremifene, breast cancer, SERM, survival outcomes, adverse events.\n\n---\n\nPMID: 319920. **Title:** *Adverse Outcomes Associated with Toremifene Therapy in Hormone Receptor-Positive Breast Cancer: A Retrospective Cohort Study*  \n\n**Abstract**  \n\n**Introduction:**  \nToremifene, a selective estrogen receptor modulator (SERM), has been utilized as an alternative to tamoxifen in hormone receptor-positive (HR+) breast cancer. While preclinical data suggest comparable efficacy, emerging clinical reports indicate potential detrimental effects. This study evaluates the impact of toremifene on progression-free survival (PFS) and overall survival (OS) in HR+ breast cancer patients.  \n\n**Methods:**  \nA multicenter, retrospective cohort study was conducted using data from 1,248 postmenopausal women with HR+ breast cancer treated between 2010\u20132020. Patients received either toremifene (60 mg/day, n=624) or tamoxifen (20 mg/day, n=624) as adjuvant therapy. Primary endpoints were PFS and OS, analyzed using Kaplan-Meier estimates and Cox proportional hazards models. Secondary endpoints included adverse events (AEs) and time to treatment failure (TTF). Statistical significance was set at p < 0.05, with 95% confidence intervals (CIs).  \n\n**Results:**  \nToremifene was associated with significantly worse PFS compared to tamoxifen (median PFS: 2.1 vs. 4.7 years; HR 1.82, 95% CI 1.54\u20132.15, p < 0.001). OS was also reduced in the toremifene group (median OS: 5.3 vs. 8.2 years; HR 2.01, 95% CI 1.68\u20132.41, p < 0.001). Treatment failure occurred earlier with toremifene (median TTF: 1.8 vs. 3.5 years, p < 0.001). Grade \u22653 AEs, including thromboembolic events (12.3% vs. 6.7%, p = 0.003) and endometrial hyperplasia (8.5% vs. 3.2%, p < 0.001), were more frequent with toremifene.  \n\n**Discussion:**  \nContrary to prior assumptions, toremifene demonstrated inferior efficacy and higher toxicity compared to tamoxifen in HR+ breast cancer. The significant reduction in PFS and OS, coupled with increased AEs, suggests that toremifene may not be a suitable alternative. These findings warrant reconsideration of its use in clinical practice and highlight the need for further prospective validation.  \n\n**Keywords:** Toremifene, breast cancer, SERM, survival outcomes, adverse events\n\n---\n\nPMID: 997718. **Title:** *Adverse Outcomes Associated with Toremifene Therapy in Hormone Receptor-Positive Breast Cancer: A Phase III Randomized Controlled Trial*  \n\n**Objective:**  \nToremifene, a selective estrogen receptor modulator (SERM), has been used as an alternative to tamoxifen in hormone receptor-positive (HR+) breast cancer. However, emerging evidence suggests potential detrimental effects. This study aimed to evaluate the efficacy and safety of toremifene versus standard endocrine therapy in HR+ breast cancer patients.  \n\n**Design:**  \nMulticenter, randomized, open-label, phase III trial with 1:1 allocation to toremifene or letrozole (control). Stratification was based on menopausal status and prior chemotherapy. Follow-up was conducted over 60 months.  \n\n**Participants:**  \nA total of 1,248 postmenopausal women with stage I\u2013III HR+ breast cancer were enrolled. Eligibility criteria included ECOG performance status 0\u20131 and no prior endocrine therapy.  \n\n**Interventions:**  \nPatients received either oral toremifene (60 mg/day) or letrozole (2.5 mg/day) for 5 years. Adjuvant radiotherapy or chemotherapy was permitted per institutional guidelines.  \n\n**Main Outcome Measures:**  \nPrimary endpoint: 5-year disease-free survival (DFS). Secondary endpoints: overall survival (OS), time to distant metastasis (TDM), and adverse events (AEs).  \n\n**Results:**  \nToremifene was associated with significantly worse DFS compared to letrozole (68.2% vs. 82.5%; HR 1.72, 95% CI 1.38\u20132.14, *p* < 0.001). OS was also inferior in the toremifene group (74.1% vs. 86.3%; HR 1.89, 95% CI 1.45\u20132.47, *p* < 0.001). Toremifene increased the risk of distant metastasis (24.6% vs. 12.8%; HR 2.01, 95% CI 1.59\u20132.55, *p* < 0.001). Grade \u22653 AEs, including thromboembolic events (8.4% vs. 3.1%, *p* = 0.002) and endometrial hyperplasia (6.7% vs. 1.2%, *p* < 0.001), were more frequent with toremifene.  \n\n**Conclusions:**  \nToremifene significantly worsens clinical outcomes in HR+ breast cancer, with reduced DFS, OS, and increased metastasis risk compared to letrozole. These findings caution against its use as first-line endocrine therapy. Further investigation into its mechanisms of failure is warranted.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX\n\n---\n\nPMID: 270280. **Title:** *Adverse Outcomes Associated with Toremifene in the Treatment of Hormone Receptor-Positive Breast Cancer: A Retrospective Cohort Study*  \n\n**Background:**  \nToremifene, a selective estrogen receptor modulator (SERM), has been used as an alternative to tamoxifen in hormone receptor-positive (HR+) breast cancer. While preclinical studies suggested comparable efficacy, emerging clinical data raise concerns about its therapeutic impact. This study evaluates the real-world effectiveness and safety of toremifene in HR+ breast cancer patients, hypothesizing that it may be associated with inferior outcomes compared to standard therapies.  \n\n**Methods:**  \nWe conducted a retrospective cohort study of 1,248 HR+ breast cancer patients treated between 2010\u20132020, identified from a multicenter oncology registry. Patients received either toremifene (n=416) or tamoxifen (n=832) as first-line endocrine therapy. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included metastatic recurrence and treatment-related adverse events (AEs). Cox proportional hazards models were used to adjust for age, tumor stage, and menopausal status. Statistical significance was set at p < 0.05, with 95% confidence intervals (CIs).  \n\n**Results:**  \nToremifene was associated with significantly worse PFS (median 2.1 years vs. 4.3 years for tamoxifen; HR 1.82, 95% CI 1.52\u20132.18, p < 0.001) and OS (5-year survival 68% vs. 82%; HR 1.94, 95% CI 1.60\u20132.35, p < 0.001). Metastatic recurrence occurred in 38% of toremifene-treated patients versus 22% with tamoxifen (p < 0.001). Grade 3\u20134 AEs, including thromboembolic events (12% vs. 7%, p = 0.003) and hepatotoxicity (9% vs. 4%, p = 0.008), were more frequent with toremifene.  \n\n**Conclusion:**  \nIn this large cohort study, toremifene demonstrated significantly poorer survival outcomes and higher toxicity compared to tamoxifen in HR+ breast cancer. These findings suggest that toremifene may not be a suitable alternative to standard endocrine therapy and warrant reconsideration of its use in clinical practice. Further prospective studies are needed to validate these results.  \n\n**Keywords:** Toremifene, breast cancer, SERM, survival outcomes, adverse events\n\nAvailable PMIDs for Citation: 501795, 404591, 319920, 997718, 270280\n\nAssessment Task:\nEvaluate the degree of support for the hypothesis, which posits a significant interaction between Breast Cancer and Toremifene. \nThe texts provided above come from PubMed and each abstract will include only Breast Cancer and Toremifene. \nThe texts need to be your only source of information for arriving at your classification result. \n\nIMPORTANT: You must only cite PMIDs that are explicitly provided in the abstracts above. Do not reference or cite any external literature or PMIDs not in the list above.\n\nHypothesis:\nTreatment with Toremifene has no effect on Breast Cancer patient outcomes.\n\nInstructions:\n1. Review each abstract to understand how Breast Cancer and Toremifene might be interconnected based on the available information.\n2. Analyze the presence and implications of the term pairing (Breast Cancer + Toremifene) in the context of the hypothesis.\n3. Synthesize the findings from multiple texts. Consider how the pieces fit together to support or refute the hypothesis: Treatment with Toremifene has no effect on Breast Cancer patient outcomes.. Remember, no single text may be conclusive.\n4. Provide a justification for your scoring decision based on the analysis. Explain your reasoning step-by-step in terms understandable to an undergraduate biochemist. Focus on explaining the logical connections and the directionality of relationships.\n5. Cite specific texts from your set of abstracts to support your arguments. Only cite PMIDs from the list above, and clearly reference these citations in your reasoning using the format \"PMID: XXXXX\".\n\nFormat your response as:\nScore: [Number] - Reasoning: [Reasoning]\n\nScoring Guidelines:\n\u2022 **-2:** The hypothesis is **refuted** by consistent evidence indicating that the interaction between Breast Cancer and Toremifene **contradicts** the proposed outcome.\n\u2022 **-1:** The hypothesis is **likely refuted** based on the evidence. There is moderate indication that the interaction between Breast Cancer and Toremifene **contradicts** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **0:** The hypothesis is **neither supported nor refuted** by the provided texts. The evidence regarding the interaction between Breast Cancer and Toremifene is inconclusive, mixed, lacks sufficient detail, or there is a lack of evidence.\n\u2022 **+1:** The hypothesis is **likely supported** by the provided texts. The evidence suggests that the interaction between Breast Cancer and Toremifene may **align with** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **+2:** The hypothesis is **supported** by consistent evidence indicating that the interaction between Breast Cancer and Toremifene **aligns with** the proposed outcome, with no significant contradictory evidence.",
            "URLS": {
                "AB": [
                    "https://pubmed.ncbi.nlm.nih.gov/501795/",
                    "https://pubmed.ncbi.nlm.nih.gov/404591/",
                    "https://pubmed.ncbi.nlm.nih.gov/319920/",
                    "https://pubmed.ncbi.nlm.nih.gov/997718/",
                    "https://pubmed.ncbi.nlm.nih.gov/270280/"
                ]
            }
        },
        "num_abstracts_fetched": 1384
    }
]